BioCentury
ARTICLE | Company News

Basilea's ceftobiprole approved for pneumonia in Europe

October 23, 2013 11:55 PM UTC

Basilea Pharmaceutica AG (SIX:BSLN) said ceftobiprole was approved under the EU's decentralized procedure to treat community-acquired pneumonia (CAP) and hospital-acquired pneumonia (HAP), excluding ventilator-associated pneumonia (VAP), in adults. Basilea declined to disclose the reference member state. Ceftobiprole, a broad-spectrum cephalosporin antibiotic with activity against methicillin-resistant Staphylococcus aureus (MRSA), has twice been rejected by both EMA and FDA for complicated skin and skin structure infections (cSSSIs) in part because of concerns over the reliability of data from clinical trials for ceftobiprole in complicated skin indications that were sponsored by Basilea's former partner Johnson & Johnson (NYSE:JNJ). ...